The Cystic Fibrosis Foundation today applauds the Food and Drug Administration's approval of Kalydeco™ (ivacaftor; previously known as VX-770), a major advance in the search for a cure for cystic fibrosis.
Dec. 21, 2012
|
2 min read
Jan. 31, 2012
|
3 min read